| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
The National Cancer Institute-Children's Oncology Group (NCI-COG) Pediatric Molecular Analysis for Therapy Choice (MATCH) trial provides a framework for biomarker-driven early phase trials of targeted therapies in pediatric and young adult cancer patients across the United States. Pediatric MATCH enrolled more than 1,300 patients with treatment-refractory cancers, offering access to molecular screening and investigational targeted therapies.
To further advance this, matched diagnostic, refractory tumor, and normal samples from Pediatric MATCH cases were molecularly characterized, creating one of the largest comprehensive data sets available for childhood cancers. This analysis has the potential to provide novel insights into the genetics of refractory pediatric, adolescent, and young adult cancers, as well as inform potential therapeutic strategies.
The following molecular characterization assays were performed:
- Tumor whole exome sequencing (WES)
- Tumor whole genome sequencing (WGS)
- Tumor RNA sequencing (RNA-seq)
- Blood whole exome sequencing (WES)
- Blood whole genome sequencing (WGS)
- Study Weblinks:
- Study Design:
- Tumor vs. Matched-Normal
- Study Type:
- Tumor vs. Matched-Normal
- Total number of consented subjects: 1239
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
-
- Clinical Trials
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Neoplasms
- Sarcoma
- Brain Neoplasms
- Authorized Data Access Requests
- Study Attribution
-
-
Co-Principal Investigators
- Donald Williams (Will) Parsons, MD, PhD. Texas Children's Hospital, Houston, TX, USA.
- Katherine A. Janeway, MD, MMSc. Dana-Farber Cancer Institute, Boston, MA, USA.
- Doug Hawkins, MD. Children's Oncology Group, Seattle, WA, USA.
-
Program Directors
- Nita Seibel, MD. National Cancer Institute, Bethesda, MD, USA.
- Malcolm Smith, MD PhD. National Cancer Institute, Bethesda, MD, USA.
-
Sequencing Centers
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
- Broad Institute, Boston, MA, USA.
-
Co-Principal Investigators